CELULARITY INC-A (CELU) Fundamental Analysis & Valuation
NASDAQ:CELU • US1511902041
Current stock price
1.33 USD
+0.07 (+5.56%)
At close:
1.29 USD
-0.04 (-3.01%)
After Hours:
This CELU fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CELU Profitability Analysis
1.1 Basic Checks
- In the past year CELU has reported negative net income.
- In the past year CELU has reported a negative cash flow from operations.
- In the past 5 years CELU reported 4 times negative net income.
- CELU had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- CELU's Return On Assets of -70.65% is on the low side compared to the rest of the industry. CELU is outperformed by 63.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.65% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-58.77%
ROA(5y)-40.28%
ROE(3y)-375.51%
ROE(5y)-245.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CELU has a better Gross Margin (50.61%) than 75.24% of its industry peers.
- CELU's Gross Margin has improved in the last couple of years.
- CELU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.74%
GM growth 5YN/A
2. CELU Health Analysis
2.1 Basic Checks
- CELU does not have a ROIC to compare to the WACC, probably because it is not profitable.
- CELU has more shares outstanding than it did 1 year ago.
- CELU has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, CELU has a worse debt to assets ratio.
2.2 Solvency
- CELU has an Altman-Z score of -13.30. This is a bad value and indicates that CELU is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of CELU (-13.30) is worse than 78.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.3 |
ROIC/WACCN/A
WACC6.67%
2.3 Liquidity
- CELU has a Current Ratio of 0.16. This is a bad value and indicates that CELU is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Current ratio value of 0.16, CELU is not doing good in the industry: 93.42% of the companies in the same industry are doing better.
- CELU has a Quick Ratio of 0.16. This is a bad value and indicates that CELU is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of CELU (0.12) is worse than 93.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.16 | ||
| Quick Ratio | 0.12 |
3. CELU Growth Analysis
3.1 Past
- The earnings per share for CELU have decreased strongly by -119.42% in the last year.
- The Revenue for CELU has decreased by -15.81% in the past year. This is quite bad
- The Revenue has been growing by 36.47% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-119.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.97%
Revenue 1Y (TTM)-15.81%
Revenue growth 3Y36.47%
Revenue growth 5YN/A
Sales Q2Q%-43.16%
3.2 Future
- The Earnings Per Share is expected to decrease by -119.65% on average over the next years. This is quite bad
- Based on estimates for the next years, CELU will show a very strong growth in Revenue. The Revenue will grow by 98.27% on average per year.
EPS Next Y-752.63%
EPS Next 2Y-119.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year27.37%
Revenue Next 2Y49.72%
Revenue Next 3Y144.15%
Revenue Next 5Y98.27%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. CELU Valuation Analysis
4.1 Price/Earnings Ratio
- CELU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year CELU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- CELU's earnings are expected to decrease with -119.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-119.65%
EPS Next 3YN/A
5. CELU Dividend Analysis
5.1 Amount
- CELU does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CELU Fundamentals: All Metrics, Ratios and Statistics
1.33
+0.07 (+5.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-17 2025-11-17/dmh
Earnings (Next)05-07 2026-05-07/amc
Inst Owners12.94%
Inst Owner Change-2.63%
Ins Owners15.43%
Ins Owner Change10.25%
Market Cap38.36M
Revenue(TTM)40.58M
Net Income(TTM)-80.71M
Analysts82.86
Price Target6.12 (360.15%)
Short Float %2.4%
Short Ratio2.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.58%
Min EPS beat(2)-33.33%
Max EPS beat(2)42.48%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.95 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.34
EYN/A
EPS(NY)-2.8
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS1.41
BVpS-0.7
TBVpS-1.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.65% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.61% | ||
| FCFM | N/A |
ROA(3y)-58.77%
ROA(5y)-40.28%
ROE(3y)-375.51%
ROE(5y)-245.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.74%
GM growth 5YN/A
F-Score1
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.16 | ||
| Quick Ratio | 0.12 | ||
| Altman-Z | -13.3 |
F-Score1
WACC6.67%
ROIC/WACCN/A
Cap/Depr(3y)39.96%
Cap/Depr(5y)N/A
Cap/Sales(3y)16.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-119.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.97%
EPS Next Y-752.63%
EPS Next 2Y-119.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.81%
Revenue growth 3Y36.47%
Revenue growth 5YN/A
Sales Q2Q%-43.16%
Revenue Next Year27.37%
Revenue Next 2Y49.72%
Revenue Next 3Y144.15%
Revenue Next 5Y98.27%
EBIT growth 1Y-21.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y88.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y89.75%
OCF growth 3YN/A
OCF growth 5YN/A
CELULARITY INC-A / CELU Fundamental Analysis FAQ
What is the ChartMill fundamental rating of CELULARITY INC-A (CELU) stock?
ChartMill assigns a fundamental rating of 1 / 10 to CELU.
What is the valuation status of CELULARITY INC-A (CELU) stock?
ChartMill assigns a valuation rating of 0 / 10 to CELULARITY INC-A (CELU). This can be considered as Overvalued.
Can you provide the profitability details for CELULARITY INC-A?
CELULARITY INC-A (CELU) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for CELU stock?
The Earnings per Share (EPS) of CELULARITY INC-A (CELU) is expected to decline by -752.63% in the next year.